Total Return Level Chart

Historical Total Return Level Data

View and export this data back to 1994. Start Trial.
Date Value
November 17, 2026 250.79
November 16, 2026 251.65
November 13, 2026 253.40
November 12, 2026 250.48
November 11, 2026 253.40
November 10, 2026 253.25
November 09, 2026 254.87
November 06, 2026 248.35
November 05, 2026 243.93
November 04, 2026 254.46
November 03, 2026 248.93
November 02, 2026 249.01
October 30, 2026 253.62
October 29, 2026 249.65
October 28, 2026 244.05
October 27, 2026 252.73
October 26, 2026 252.26
October 23, 2026 250.69
October 22, 2026 253.84
October 21, 2026 240.98
October 20, 2026 243.10
October 19, 2026 233.48
October 16, 2026 232.65
October 15, 2026 235.35
October 14, 2026 232.83
Date Value
October 13, 2026 228.90
October 12, 2026 229.41
October 09, 2026 225.71
October 08, 2026 218.43
October 07, 2026 222.15
October 06, 2026 222.89
October 05, 2026 223.59
October 02, 2026 219.88
October 01, 2026 222.82
September 30, 2026 225.88
September 29, 2026 227.07
September 28, 2026 228.69
September 25, 2026 227.60
September 24, 2026 226.36
September 23, 2026 227.53
September 22, 2026 225.36
September 21, 2026 219.07
September 18, 2026 215.50
September 17, 2026 219.05
September 16, 2026 216.01
September 15, 2026 216.17
September 14, 2026 217.36
September 11, 2026 217.15
September 10, 2026 215.43
September 09, 2026 210.73

Total Return Level Definition

The total return level allows investors to view the performance of a security inclusive of both price appreciation and dividends/distributions. Total return level is seen as the most accurate calculation that produces returns consistent with most other sources.

Read full definition.

Total Return Level Range, Past 5 Years

View Total Return Level Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Return Level Benchmarks

View Total Return Level Benchmarks
Start Trial
Gilead Sciences, Inc. 249.53
AbbVie, Inc. 507.46
Amgen, Inc. 685.72
Eli Lilly & Co. 3744.66
Regeneron Pharmaceuticals, Inc. 966.64